Dr. Wittlin received his M.D. from Tel Aviv University with honors. He then completed his residency training in internal medicine at Booth Memorial Medical Center, followed by an endocrinology fellowship at New York University Medical Center. He served as Chief of Endocrinology and subsequently Assistant Chairman of Medicine at Booth Memorial Medical Center for a twelve-year period. He moved to Rochester in 1993. Dr. Wittlin's major clinical interest, apart from general endocrinology, is treatment of diabetes, especially new modalities of therapy with an emphasis on insulin pumps and continuous glucose monitoring. His research interests have mainly focused on novel diabetes treatments, preservation of beta cell function, new modalities for assessing diabetes and postprandial glucose control, and assessment of cardiovascular risk in diabetes.

Certified Specialties

Endocrinology, Diabetes and Metabolism - American Board of Internal Medicine

Internal Medicine - American Board of Internal Medicine

Faculty Appointments

Professor (Part-Time) - Department of Medicine, Endocrine/Metabolism (SMD)

Credentials

Residency & Fellowship

Fellowship, Internal Medicine, Endocrinology, Diabetes & Metabolism, New York University Langone Medical Center. 1979 - 1981

Residency, Internal Medicine, New York-Presbyterian Queens. 1977 - 1979

Internship, Internal Medicine, New York-Presbyterian Queens. 1976 - 1976

Education

MD | Sackler School of Medicine (Tel Aviv University). 1975

Publications

Journal Articles

Exploring the Impact of Device Sourcing on Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients With Diabetes: Retrospective Claims Analysis.

Allaire J, Dennis C, Masturzo A, Wittlin S

JMIR diabetes.. 2024 July 229 :e58832. Epub 07/22/2024.

Refining risk in diabetes and CAD with SPECT MPI: New insights and future challenges.

Naqvi SY, Wittlin SD, Schwartz RG

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.. 2019 August 26 (4):1103-1106. Epub 02/05/2018.

Chronomedicine and type 2 diabetes: shining some light on melatonin.

Forrestel AC, Miedlich SU, Yurcheshen M, Wittlin SD, Sellix MT

Diabetologia.. 2017 May 60 (5):808-822. Epub 12/16/2016.

Improvement in glycemic control after left ventricular assist device implantation in advanced heart failure patients with diabetes mellitus.

Choudhary N, Chen L, Kotyra L, Wittlin SD, Alexis JD

ASAIO journal : a peer-reviewed journal of the American Society for Artificial Internal Organs.. 2014 60 (6):675-80. Epub 1900 01 01.

Two cases of malignant struma ovarii with metastasis to pelvic bone.

Steinman RA, De Castro IO, Shrayyef M, Chengazi V, Giampoli E, Van Der Sloot P, Calvi LM, Wittlin SD, Hammes SR, Hou R

Gynecologic and obstetric investigation.. 2013 75 (2):139-44. Epub 02/06/2013.

Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study.

Tandon S, Wackers FJ, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH,

Diabetes & vascular disease research.. 2012 April 9 (2):124-30. Epub 01/06/2012.

Hypercalcemia in two patients with sarcoidosis and Mycobacterium avium intracellulare not mediated by elevated vitamin D metabolites.

Shrayyef MZ, Depapp Z, Cave WT, Wittlin SD

The American journal of the medical sciences.. 2011 October 342 (4):336-40. Epub 1900 01 01.

Adrenal artery aneurysm encountered during laparoscopic adrenalectomy for pheochromocytoma.

Glocker R, Ruan DT, Gillespie D, Wittlin S, Dombrowski D, Moalem J

Journal of vascular surgery.. 2011 July 54 (1):216-8. Epub 02/18/2011.

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.

Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE,

Annals of internal medicine.. 2010 March 16152 (6):346-57. Epub 1900 01 01.

Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects.

Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR,

Clinical endocrinology.. 2010 January 72 (1):59-69. Epub 05/04/2009.

Platelet proteome changes associated with diabetes and during platelet storage for transfusion.

Springer D, Miller J, Spinelli S, Pasa-Tolic L, Purvine S, Daly D, Zangar R, Jin S, Blumberg N, Francis C, Taubman M, Casey A, Wittlin S, Phipps R

Journal of proteome research.. 2009 May 8 (5):2261-72. Epub 1900 01 01.

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.

Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE,

JAMA.. 2009 April 15301 (15):1547-55. Epub 1900 01 01.

Pheochromocytoma: presenting with regular cyclic blood pressure and inverted Takotsubo cardiomyopathy.

Jindal V, Baker ML, Aryangat A, Wittlin SD, Bisognano JD, Richter HS

The journal of clinical hypertension.. 2009 February 11 (2):81-6. Epub 1900 01 01.

Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.

Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB,

Diabetes technology & therapeutics.. 2008 February 10 (1):1-10. Epub 1900 01 01.

Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study.

Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE,

Diabetes care.. 2007 November 30 (11):2892-8. Epub 08/06/2007.

The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands.

O'Brien JJ, Ray DM, Spinelli SL, Blumberg N, Taubman MB, Francis CW, Wittlin SD, Phipps RP

Prostaglandins & other lipid mediators.. 2007 January 82 (1-4):68-76. Epub 07/10/2006.

1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes.

Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S

Diabetes care.. 2006 June 29 (6):1214-9. Epub 1900 01 01.

Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes.

Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, Gosmanov NR, Welle SL, Gerich JE

American journal of physiology. Endocrinology and metabolism.. 2006 January 290 (1):E67-E77. Epub 08/16/2005.

Treating the spectrum of type 2 diabetes: emphasis on insulin pump therapy.

Wittlin SD

The Diabetes educator.. 2006 32 (1 Suppl):39S-46S. Epub 1900 01 01.

Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.

Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE,

Diabetes care.. 2004 August 27 (8):1954-61. Epub 1900 01 01.

Pathways for glucose disposal after meal ingestion in humans.

Woerle HJ, Meyer C, Dostou JM, Gosmanov NR, Islam N, Popa E, Wittlin SD, Welle SL, Gerich JE

American journal of physiology. Endocrinology and metabolism.. 2003 April 284 (4):E716-25. Epub 12/10/2002.

Tetracaine, propranolol and trifluoperazine inhibit thyrotropin releasing hormone-induced prolactin secretion from GH3 cells by displacing membrane calcium: further evidence that TRH acts to mobilize cellular calcium.

Thaw C, Wittlin SD, Gershengorn MC

Endocrinology.. 1982 December 111 (6):2138-40. Epub 1900 01 01.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.8

Likelihood of recommending this care provider to others

4.7

Explanations the care provider gave you about your problem or condition

4.8

Care provider's efforts to include you in decisions about your care

4.8

Concern the care provider showed for your questions or worries

4.8

Patient Comments

5.0

Everyone is so knowledgeable, caring, helpful, and kind

Dec 13, 2024

5.0

Dr. Wittlin always is wonderful!

Dec 06, 2024

5.0

Dr. Wittlin was extra relaxed during this appointment.

Dec 01, 2024

5.0

Dr Wittlin great guy

Nov 30, 2024

5.0

Doctor Wittlin is a wonderful doctor! Very caring and friendly.

Nov 26, 2024

5.0

Dr. Steve Wittlin is superb. A jewel to have in your endocrine unit.

Nov 24, 2024

4.0

Over all is good, better than another facility. But, I still feel like I'm not being listened to. Dr did listen to me when I said [...] I feel better, don't change meds! And he listened. [...]

Nov 02, 2024

5.0

Dr. Wittlin is the best!

Oct 06, 2024

5.0

Dr. Witlin is great.

Sep 26, 2024

5.0

Dr. Wittlin is awesome! He listens, has a great demeanor, and answered questions in a way I could understand.

Sep 07, 2024

5.0

Very good 5

Aug 09, 2024

1.4

I felt rushed, Dr W told me patients before me were late putting him behind. I felt like I didn't matter, wasn't important enough to warrant my questions and concerns to be addressed.

May 04, 2024

5.0

I would recommend Dr. Wittlin & to everyone.

Apr 23, 2024

5.0

Dr. Wittlin put me at ease regarding my condition.

Apr 16, 2024

Dr. Wittlin is the best.

Dec 17, 2023

4.2

Dr. Wittlin is a good person/professional.

Nov 22, 2023

5.0

Doctor Wittlin is great! Very caring, friendly.

Oct 26, 2023

5.0

Dr. Wittlin is incredibly personable and kind. He provides great care, and I would recommend him to anyone in need of an endocrinologist.

Sep 17, 2023

5.0

Dr. Wittlin was excellent as a doctor and had a great sense of humor that made the visit easy.

Aug 15, 2023

5.0

Dr. Wittlin is always kind, considerate and listens to my concerns. I've been seeing him for many years.

Jun 27, 2023

5.0

He put me at ease and showed genuine interest

Jun 17, 2023

I love Dr Wittlin. I've been a patient of his since I was diagnosed with diabetes in 1995.

Jun 11, 2023

Dr. Wittlin is wonderful. He is always on top of my blood work, medications and overall health. I sincerely appreciate his excellent care.

May 18, 2023

5.0

Doctor Wittlin is fantastic! Very friendly and helpful and seems to really enjoy his job.

Apr 26, 2023

5.0

No one better than Dr. Wittlin

Apr 20, 2023

3.9

This a new doctor getting to know one another and trust.

Apr 10, 2023

Dr. Wittlin is kind, knowledgeable, and treats me like I have a brain in my head, which I very much appreciate.

Mar 26, 2023

Dr. Wittlin is an exemplar of excellence for empathy and intelligence.

Dec 23, 2022

Dr. Wittlin is one of the best doctors I've ever dealt with. If not the best.

Oct 30, 2022

5.0

Dr Wittlin is a good doctor!

Oct 26, 2022

5.0

Doctor Wittlin is a fantastic doctor!

Oct 26, 2022

It was a very good experience. Dr. Explained what I needed ti do to improve my A1C.

Sep 26, 2022

Dr Wittlin is very smart and caring as well Was told he was the best and I believe It

Sep 23, 2022

Dr. Wittlin is attentive, thorough, and treats me with respect.

Sep 10, 2022

I spoke with my doctor only for short time but Everything I needed to do was communicatedTo me !

Mar 23, 2022

5.0

He is a gem

Mar 05, 2022

Dr Wittlin has the best bedside manner. Easy to talk to and listens to what I have to say. I highly recommend.

Mar 04, 2022